Alkem Laboratories Ltd (NSE: ALKEM) and Glenmark Pharmaceuticals Limited (NSE: GLENMARK) are both listed in the Medicinal Chemicals and Botanical Products industry. Alkem Laboratories has a market capitalisation of ₹61,636 Cr and Glenmark Pharmaceuticals ₹67,220 Cr, as of 9 Nov 2026. Their P/E ratios are 26.8 and 49.4 respectively. Return on equity is 17.56% for Alkem Laboratories and 14.07% for Glenmark Pharmaceuticals. Over one year, Alkem Laboratories's share price is down 2.0% and Glenmark Pharmaceuticals's is up 40.7%.
| Metric | Alkem Laboratories | Glenmark Pharmaceuticals |
|---|---|---|
| NSE Symbol | ALKEM | GLENMARK |
| BSE Code | 539523 | 532296 |
| Share Price | ₹5,398.50 | ₹2,671.10 |
| Market Cap | ₹61,636 Cr | ₹67,220 Cr |
| P/E Ratio | 26.8 | 49.4 |
| Return on Equity | 17.56% | 14.07% |
| Return on Assets | 8.43% | 14.11% |
| Dividend Yield | 0.39% | 0.21% |
| Beta (1Y) | 0.29 | 0.4 |
| 1-Year Price Change | -2.0% | +40.7% |
| 3-Month Price Change | -3.6% | +18.6% |
| 52-Week Range | ₹4,811.00 – ₹5,933.50 | ₹1,807.00 – ₹2,714.00 |
| Latest Quarter | Q1 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹3,740 Cr | ₹4,157 Cr |
| Quarterly Net Profit | ₹521 Cr | ₹264 Cr |
| Net Margin | 13.9% | 6.3% |
| EPS (Basic, Quarter) | ₹43.49 | ₹9.35 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neu…
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertension, central nervous system, cardiology, diabetes, contraceptives, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topica…
Glenmark Pharmaceuticals has a market capitalisation of ₹67,220 Cr, against ₹61,636 Cr for Alkem Laboratories as of 9 Nov 2026, so the two are about the same size by market cap.
Alkem Laboratories has a P/E of 26.8 and Glenmark Pharmaceuticals a P/E of 49.4 as of 9 Nov 2026.
Alkem Laboratories has a return on equity of 17.56% and Glenmark Pharmaceuticals 14.07%.
Alkem Laboratories's share price is down 2.0% over one year and Glenmark Pharmaceuticals's is up 40.7%.
Alkem Laboratories reported revenue of ₹3,740 Cr and net profit of ₹521 Cr for Q1 FY27. Glenmark Pharmaceuticals reported revenue of ₹4,157 Cr and net profit of ₹264 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.